Effectiveness of Montelukast in Reducing the Risk of Severe Dengue in Dengue Fever Patients: An Evidence-Based Case Report
Keywords:
evidence-based case report, severe dengue, dengue fever, leukotriene receptor antagonist, montelukastAbstract
Background: Dengue fever continues to spread worldwide, particularly in tropical regions. Some patients with dengue fever may progress to severe dengue, which is associated with significantly higher morbidity and mortality. Despite this, no definitive treatment has been found to prevent its progression. Montelukast, a leukotriene receptor antagonist, has shown potential in reducing plasma leakage, a key factor in the pathophysiology of severe dengue. Therefore, this study aimed to evaluate the effectiveness of montelukast in reducing the risk of severe dengue. Methods: A systematic literature search was conducted on April 16, 2025, using keywords related to montelukast and dengue across four databases, which included PubMed, Taylor and Francis, Cochrane Library, and ScienceDirect. A critical appraisal was performed using the Oxford Centre for Evidence-Based Medicine framework, evaluating the validity, importance, and applicability of each study. The primary outcomes were the incidence of dengue shock syndrome and dengue with warning signs. The secondary outcomes included mortality rate and hospitalization duration. Results: This study included three studies involving a total of 1057 patients. Montelukast is associated with a reduced incidence of dengue shock syndrome and shorter duration of hospitalization. However, the effect of montelukast on dengue with warning signs and mortality rate was inconclusive. Conclusion: Montelukast shows potential as an adjuvant therapy in preventing the progression of dengue fever to severe dengue. However, further research is required before montelukast can be widely recommended for dengue fever patients in daily clinical practice and possibly integrated into dengue fever clinical guidelines.References
De Almeida RR, Paim B, de Oliveira SA, et al. Dengue hemorrhagic fever: a state-of-the-art review focused on pulmonary involvement. Lung. 2017;195:389-95. 10.1007/s00408-017-0021-6.
Wilder-Smith A, Murray, Quam M. Epidemiology of dengue: past, present and prospects. Clin Epidemiol. 2013;5:299-309. 10.2147/CLEP.S34440.
Tian N, Zheng JX, Guo ZY, et al. Dengue incidence trends and its burden in major endemic regions from 1990 to 2019. Trop Med Infect Dis. 2022;7:180. 10.3390/tropicalmed7080180.
Khan MB, Yang ZS, Lin CY, et al. Dengue overview: an updated systematic review. J Infect Public Health. 2023;16:1625-42. 10.1016/j.jiph.2023.08.001.
Ajlan BA, Alafif MM, Alawi MM, et al. Assessment of the new World Health Organization’s dengue classification for predicting the severity of illness and level of healthcare required. PLoS Negl Trop Dis. 2019;13:e0007144. 10.1371/journal.pntd.0007144.
Wong JM, Adams LE, Durbin AP, et al. Dengue: a growing problem with new interventions. Pediatrics. 2022;149:e2021055522. 10.1542/peds.2021-055522.
Chagas GC, Rangel AR, Noronha LM, et al. Risk factors for mortality in patients with dengue: a systematic review and meta-analysis. Trop Med Int Health. 2022;27:656-68. 10.1111/tmi.13797.
Londono-Renteria B, Marinez-Angarita JC, Troupin A, et al. Role of mast cells in dengue virus pathogenesis. DNA Cell Biol. 2017;36:423-7. 10.1089/dna.2017.3765.
Jiang H, Zhang Y, Wu Y, et al. Identification of montelukast as flavivirus NS2B-NS3 protease inhibitor by inverse virtual screening and experimental validation. Biochem Biophys Res Commun. 2022;606:87-93. 10.1016/j.bbrc.2022.03.064.
St John AL, Rathore AP, Raghavan B, et al. Contributions of mast cells and vasoactive products, leukotrienes, and chymase, to dengue virus-induced vascular leakage. Elife. 2013;2:e00481. 10.7554/eLife.00481.
Center for Evidence-Based Medicine. Critical appraisal tools [Internet]. University of Oxford; [cited YEAR]. Available from: https://www.cebm.net/2014/06/critical-appraisal/.
Dev A, Singh RB, Arun N, et al. The efficacy of montelukast in reducing the risk of warning signs and subsequent dengue shock syndrome in adult dengue fever patients. Cureus. 2024;16:e61603. 10.7759/cureus.61603.
Nitinai N, Nasomsong W, Chuerboonchai W, et al. Effect of montelukast in preventing dengue with warning signs among patients with dengue: a multicenter, randomized, double-blind, placebo-controlled trial. PLoS Negl Trop Dis. 2024;18:e0011927. 10.1371/journal.pntd.0011927.
Ahmad A, Waseem T, Butt NF, et al. Montelukast reduces the risk of dengue shock syndrome in dengue patients. Trop Biomed. 2018;35:1115-22.
Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10:440-52. 10.1038/nri2782.
Kunder CA, St John AL, Abraham SN. Mast cell modulation of the vascular and lymphatic endothelium. Blood. 2011;118:5383-93. 10.1182/blood-2011-07-358432.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Nicholas Jason Wijaya, Sharifah Shakinah, Leonard Nainggolan, Erni Juwita Nelwan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
